Oncologists at Huaxi Hospital in China’s eastern Sichuan province are preparing to start what appears to be the world’s first human clinical trial using the gene editing technology CRISPR-Cas9, to treat patients with advanced non-small cell lung cancer.
Led by Lu You, the head of the hospital’s lung cancer division, the study has obtained ethics committee clearance and will start in August in 15 patients with metastatic NSCLC who have failed previous chemotherapy,